Prasugrel Hcl
Brand names: Effient, Prasugrel Hcl
At a glance
- Medicare prescriptions, 2024
- 184,108
- Medicare drug cost
- $14.1M
- Average cost per prescription
- $76.74
- Clinicians who prescribed it
- 7,065
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows: Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI.
From the FDA-approved prescribing information (label dated September 2022). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: BLEEDING RISK Effient can cause significant, sometimes fatal, bleeding. Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack (TIA) or stroke. In patients ≥75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered. Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery. Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g., warfarin, heparin,…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Cardiology 33.7%
- Interventional Cardiology 29.7%
- Nurse Practitioners 18.2%
- Physician Assistants 5.8%
- Internal Medicine 4.9%
- Family Medicine 4.8%
- Vascular Surgery 0.7%
- Cardiac Electrophysiology 0.4%
- Hospitalist 0.2%
- Geriatric Medicine 0.2%
- General Practice 0.2%
- Heart Failure & Transplant Cardiology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 5% from 2019 to 2024.
Biggest change by state since 2019
- Michigan +36%
- Missouri +32%
- Arkansas +25%
- Ohio +16%
- North Carolina +15%
- California (smallest change) −21%
- South Carolina (smallest change) −19%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Cosette Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | yellow hexagon (6 sided) tablet, 7 mm | 5 5121 |
| 10 mg | brown hexagon (6 sided) tablet, 11 mm | 10 5123 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
4 recalls since 2020
- Aug 2026 · Golden State Medical Supply Inc. · Class II
Failed Dissolution Specifications. Notification from the manufacturer that lot is being recalled due to failed dissolution - Aug 2026 · Mylan Pharmaceuticals Inc · Class II
Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria - Mar 2025 · Golden State Medical Supply Inc. · Class II
Failed Dissolution Specifications - Feb 2025 · Mylan Pharmaceuticals Inc · Class II
Failed Dissolution Specifications - low dissolution results
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.